Patents by Inventor Xingxiang Liang

Xingxiang Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240392323
    Abstract: The present invention relates to a CRISPR-Cas13 system and use thereof, and also relates to a Cas13 protein, a fusion protein, and a guide polynucleotide. The Cas13 protein has at least 90% sequence identity compared to SEQ ID NO: 1. The fusion protein comprises the Cas13 protein fused to a protein domain and/or a polypeptide tag. The guide polynucleotide comprises a same-direction repetition sequence and a guide sequence that has been engineered to hybridize with the target RNA. The same-direction repetition sequence has at least 70% sequence identity to any of SEQ ID NOs: 3 and 80-87. The CRISPR-Cas13 system comprises the Cas13 protein that has at least 90% sequence identity to SEQ ID NO: 1, or a coding nucleic acid therefor, and the guide polynucleotide or a coding nucleic acid therefor.
    Type: Application
    Filed: June 27, 2024
    Publication date: November 28, 2024
    Inventors: Junbin Liang, Xingxiang Liang, Yang Sun, Hui Xu, Kaiwei Si, Qiuting Li, Zhiqin Peng, Desheng Huangfu
  • Publication number: 20240279630
    Abstract: The present disclosure relates to an isolated Cas13 protein and use thereof. The amino acid sequence of the isolated Cas13 protein comprises a sequence having ?50% sequence identity with the sequence as shown in any one of SEQ ID NO: 1-SEQ ID NO: 7, and SEQ ID NO: 60. The Cas13 protein is a Cas13 enzyme with an endonuclease activity, which can be used in a CRISPR/Cas system to achieve targeting and modification of a target nucleic acid, enriching the enzymes and systems available in a CRISPR-C as editing system.
    Type: Application
    Filed: May 2, 2024
    Publication date: August 22, 2024
    Inventors: Junbin Liang, Xingxiang Liang, Yang Sun, Hui Xu, Zhiqin Peng, Kaiwei Si, Desheng Huangfu
  • Patent number: 11524060
    Abstract: Disclosed are an attenuation system and the use thereof for attenuating plasmodia, specifically the use of an EF1g gene for attenuating plasmodia. The attenuation system regulates the expression or degradation of the EF1g gene by using a regulatory system, thereby controlling the growth of plasmodia and achieving the attenuation of plasmodia.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: December 13, 2022
    Assignee: GUANGZHOU CAS LAMVAC BIOTECH CO., LTD
    Inventors: Xingxiang Liang, Jianhua Su, Meiling Wang, Ying Tong, Yongchao Yao, Li Qin, Xiaoping Chen
  • Publication number: 20210145953
    Abstract: Disclosed are an attenuation system and the use thereof for attenuating plasmodia, specifically the use of an EF1g gene for attenuating plasmodia. The attenuation system regulates the expression or degradation of the EF1g gene by using a regulatory system, thereby controlling the growth of plasmodia and achieving the attenuation of plasmodia.
    Type: Application
    Filed: April 26, 2018
    Publication date: May 20, 2021
    Applicant: GUANGZHOU CAS LAMVAC BIOTECH CO., LTD
    Inventors: Xingxiang Liang, Jianhua Su, Meiling Wang, Ying Tong, Yongchao Yao, Li Qin, Xiaoping Chen